definiens: shall mean all patents, patent applications, and invention disclosures ( all as listed onExhibit 1.67 ) and all information, materials and other subject matter, and improvements thereof, relating to ( i ) mutants or theuse thereof in screening, ( ii ) the use of novel protein engineering techniques and their application in drug discovery,(iii ) target - directed fragment discovery and maturation to produce drug leads, including monophores, extenders and fragmentsand monophore, extender and fragment libraries for such purposes, or ( iv ) covalent tethering and techniques related thereto(e.g . NMR, X - ray, mass spec . AUC, Biacore ) and its use to discover fragments and test binding hypotheses of fragments andleads : ( a ) controlled by Sunesis and/or its Controlled Affiliates prior to June 30, 2008 ; or ( b ) made by [COMPANY] Idec in thecourse of activities directed to the discovery, research, or development of Collaboration Compounds ; provided, in the case of(b ) that such item was made using or derived from Sunesis Core Technology . Sunesis Core Technology shall also include anydivisionals, continuations, continuations - in - part, reissues, reexaminations, extensions or other governmental actions whichextend any of the patent applications or patents in ( a ) or ( b ) above, and any substitutions, confirmations, registrations, revalidations or foreign counterparts of any of the foregoing